Company profile
Minerva Neurosciences, Inc.
NASDAQ: NERV · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
38DFH 16DQ 68GM —SS 49
v0.1 · 55/100 weight · provisional
↑ filing timeliness, market scale · ↓ Piotroski F, return on assets
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$293.4M
Employees
7
as of 2026-08-20
Market cap
$223.2M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02024
Net income-$293.4M-$293.4M2025
Operating income-$15.1M-$15.1M2025
Total assets$98.0M$98.0M2025
Liabilities$233.8M$233.8M2025
Equity-$140.7M-$140.7M2025
Revenue trend
FY2018 – FY2024 · USD
FY18
FY19
FY20
FY20
FY21
FY22
FY23
FY24
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Minerva Neurosciences, Inc.’s revenue?
Minerva Neurosciences, Inc. booked $0 in FY2024 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
ALX Oncology Holdings Inc.37DCytoDyn Inc.30DCapricor Therapeutics, Inc.57CEupraxia Pharmaceuticals Inc.42DCorbus Pharmaceuticals Holdings, Inc.46DImmuneering Corporation43DNeighbors
Middlesex →Key facts
CEORemy Luthringer
SectorHealthcare
IndustryBiotechnology
HeadquartersBurlington, MA
ExchangeNASDAQ: NERV
Employees7
IPO date2014-07-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.